Skip to main content
OpenTrials
Completed

NCT Number: NCT02726100

SMARTHealth Diabetes in China Using Lay Family Health Promoters

It's a community-based parallel-arm cluster Randomized Controlled Trial (RCT). An interactive mobile health management system will be developed to support lay family health promoters and healthcare staff to improve clinical outcomes for family members with Type 2 Diabetes Mellitus (T2DM). 2,000 participants from 80 sites will be chosen from urban (40 communities) and rural (40 villages) settings in Shijiazhuang City, Hebei Province.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Center of Disease Control and Prevention, Luquan, Shijiazhuang, Hebei, China

Loading trial locations.

About this study

Study design and Settings:

Cluster randomised controlled trial involving 80 sites (40 communities in urban Shijiazhuang and 40 villages in rural Shijiazhuang) and 2,000 people with T2DM.

Hypothesis:

An interactive mobile health management system can support lay family health promoters (FHP) and healthcare staff to improve clinical outcomes for family members with T2DM

Intervention:

SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM. It comprises the following core features:

  • Management support based on best practice clinical guidelines
  • Self-management tools and resources for family members
  • Password protected registration of patients and their nominated FHP to access this information
  • Population of key clinical information into a desktop application used by health care providers when applicable

Community eligibility:

  • 40 urban communities and 40 rural villages from geographically dispersed regions will be selected
  • Each community/ village must have at least one community health station providing services to ≥1,000 adult residents
  • Staff at the community health station must be willing to participate in the intervention

Statistical power:

80 clusters and a mean community cluster size of 25 participants (2,000 total) will provide 90% power to detect an absolute improvement of 10% in the primary outcome. This assumes 20% of people in the control arm will achieve ≥2 'ABC' diabetes goals ((HbA1C<7%; Blood Pressure <140/80 mmHg, LDL cholesterol <100mg/dl or 2.6mmol/L) at end of study; an intra-class correlation coefficient of 0.05, a 20% loss to follow-up, and a 2-sided significance level of 0.05. This translates to a mean reduction of 0.35% for HbA1C, 0.14 mmol/L for LDL cholesterol and 3.4mmHg for systolic BP. Primary analyses will be conducted at the patient level. Secondary analyses will be conducted at the cluster level. Sub-group analyses will be conducted at the community level (based on size and health service characteristics) and patient level (based on demographic factors (co-habitation with FHP) and clinical factors (control rate of 'ABC' risk factors at baseline).

Significance:

The Chinese government has placed prevention and treatment of diabetes as one of 11 National Basic Public Health Services. Despite great promise for mobile health (mHealth) interventions to improve access to effective healthcare, there remains uncertainty about how this can be successfully achieved. These uncertainties pose substantial dilemmas for health system planners. The findings are likely to inform policy on a scalable strategy to overcome sub-optimal access to effective health care in China.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Established T2DM
  • HbA1C >= 7%
  • Nominated family member with mobile internet access who agrees to be a family health promoter (FHP)
  • Able to provide informed consent

Exclusion criteria

Psychologically or physically unable to participate the trials.

Treatment and study plan

SMARTHealth Diabetes

Behavioral

SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.

Primary outcomes

  1. The proportion of patients achieving at least two "ABC" goals

    Time frame: 24 months

    The proportion of patients achieving at least two "ABC" goals defined as any two of the following: HbA1c <7.0%, blood pressure (BP) <140/80mmHg and LDL cholesterol <100mg/dl or 2.6mmol/L) at 24 months

Secondary outcomes

  1. The proportion of patients achieving the "A" goal

    Time frame: 24 months

    The proportion of patients achieving HbA1c <7.0% at 24 months

  2. The proportion of patients achieving the "B" goal

    Time frame: 24 months

    The proportion of patients achieving blood pressure (BP) <140/80mmHg at 24 months

  3. The proportion of patients achieving the "C" goal

    Time frame: 24 months

    The proportion of patients achieving LDL cholesterol <100mg/dl or 2.6mmol/L at 24 months

  4. The proportion of patients achieving FPG<7.0 mmol/L

    Time frame: 24 months

    The proportion of patients achieving FPG<7.0 mmol/L at 24 months

  5. Mean change in HbA1c level

    Time frame: 24 months

    Mean change in HbA1c level from baseline to 24 months

  6. Mean changes in systolic and diastolic blood pressure levels

    Time frame: 24 months

    Mean changes in systolic and diastolic blood pressure levels from baseline to 24 months

  7. Mean change in LDL cholesterol level

    Time frame: 24 months

    Mean change in LDL cholesterol level from baseline to 24 months

  8. Mean change in FPG level

    Time frame: 24 months

    Mean change in FPG level from baseline to 24 months

  9. Mean change in the Summary of Diabetes Self-Care Activities (SDSCA) from baseline to 24 month

    Time frame: 24 months

    The Summary of Diabetes Self-Care Activities is a scale to measure patients' self-management. The minimum value of each scale item is 0 and the maximum value is 7. Higher scores mean a better outcome.

Other outcomes

  1. Mean change in body mass index (BMI)

    Time frame: 24 months

    Mean change in body mass index (BMI) from baseline to 24 months

  2. Mean change in waist circumstance (WC)

    Time frame: 24 months

    Mean change in waist circumstance (WC) from baseline to 24 months

  3. Mean change in the European quality of life 5 dimensions 3 levels scale (EQ-5D-3L) index value

    Time frame: 24 months

    Mean change in the European quality of life 5 dimensions 3 levels scale (EQ-5D-3L) index value from baseline to 24 months. The minimum value of the scale is 0 and the maximum value is 1. Higher scores mean a better outcome.

  4. Mean change in the European quality of life overall self-rated visual analogue scale (EQ-VAS)

    Time frame: 24 months

    Mean change in the European quality of life overall self-rated visual analogue scale (EQ-VAS) from baseline to 24 months. The minimum value of the scale is 0 and the maximum value is 100. Higher scores mean a better outcome.

  5. Mean change in The Summary of Diabetes Self-Care Activities (SDSCA) from baseline to 24 months

    Time frame: 24 months

    Pending

  6. Mean change in urine albumin creatinine ratio (ACR)

    Time frame: 24 months

    Mean change in urine albumin creatinine ratio (ACR) from baseline to 24 months

  7. Mean change in estimated glomerular filtration rate (GFR)

    Time frame: 24 months

    Mean change in estimated glomerular filtration rate (GFR) from baseline to 24 months

Sponsors and collaborators

Lead sponsor

The George Institute for Global Health, China

Other

Collaborators

  • Global Alliance for Chronic Diseases (GACD)
  • National Health and Medical Research Council, Australia

Registry information

Official study title

Systematic Medical Assessment, Referral and Treatment for Diabetes Care in China Using Lay Family Health Promoters

Important dates

Study start
2017
Primary completion
2019
Study completion
2021
First posted
Apr 1, 2016
Registry last updated
Mar 12, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.